Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Antidiabetics Effect on Visceral Fat in T2D
NCT05032001Unknown
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of linagliptin, sitagliptin, empagliflozin and dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms). Primary endpoint: Change from baseline in visceral fat measured by bioimpedance at 12 weeks. Status: unknown.
02
Drugs
linagliptinsitagliptinempagliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05032001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032001.